Navigation Links
AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand Congress

Alachua, FL (PRWEB) May 29, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that positive data based on clinical use of Avance® Nerve Graft will be presented in an oral presentation at the 18th Federation of European Societies for Surgery of the Hand (FESSH) Congress, May 29 to June 1, 2013 in Antalya, Turkey. The main topic of the congress will be “Current Treatment of Nerve Injuries and Disorders.” AxoGen will also host a booth to exhibit its products, including the recently CE Marked AxoGuard® Nerve Protector and AxoGuard® Nerve Connector, at the FESSH Congress.

The data being presented will report on findings from the RANGER® Registry, an on-going multi-center utilization and outcomes study for Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve segmental defects. Study investigator Bauback Safa, MD, of The Buncke Clinic in San Francisco, CA, will share findings in an oral presentation titled, “Nerve Reconstruction with Processed Nerve Allografts: Outcomes from a National Multicenter Registry,” which is based on a subset of data from the RANGER® Registry focused on nerve repair in the hand.

Dr. Safa said, “I am pleased to share the positive clinical outcomes in nerve repair of the hand that have been recorded to date in the Ranger® Registry, which is the largest multi-center study of peripheral nerve repair. Restoring proper function in the nerves of the hand has historically been very challenging, with recovery dependent on many factors. Our results with hand microsurgery using the Avance® Nerve Graft at The Buncke Clinic have been very encouraging, in terms of both clinical outcomes and the fact that the product does not require a second surgical site for autograft harvest. I look forward to contributing to the scientific session at the FESSH Congress to expand awareness of this innovative, commercially available nerve graft option.”

Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve allograft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.

For more information on AxoGen and its technology, please visit

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense
2. AxoGen, Inc. Files Form S-1 Registration Statement
3. AxoGen, Inc. Announces CE Mark Approval for AxoGuard® Nerve Protector and AxoGuard® Nerve Connector
4. AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference Call
5. AxoGen, Inc. to Highlight Products at the American Academy of Orthopedic Surgeons 2013 Meeting
6. AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
7. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
8. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
9. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Diet Plans Promoting Fast Weight Loss, thus Aiding in More Restful, Uninterrupted & Satisfying Sleep
11. SlimDoggy Announces the Dog Calorie and Food Calculator Widget
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of ... company. Because it is so important to this key industry segment, Regis Technologies has ... IND Filing” on December 4th at 11am EST. , Federal law does not allow ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced that it ... IT consulting, development and support company. The purchase will expand the capability to ... to extend the services currently provided by Healthjump. , Through this ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... of a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout ... foot space and increase the number of corporate, industrial, manufacturing and government workers ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Fla. , Nov. 30, 2015   The ... (the Institute) announced today that it has finalized a ... start-up company with technology developed at Florida State University. ... research, and bridges early funding gaps for companies spinning ... research institutions. --> ...
(Date:11/30/2015)... India , November 30, 2015 ... --> adds ... trends for 2010 - 2015 with ... for a range of deal types, ... and strategic alliances. ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology: